GAUGUIN: Higher Obinutuzumab Dose Shows Promise in Non-Hodgkin ... Cancer Network “Given that CD20 has proved to be a highly successful target antigen for immunotherapeutic approaches in hematologic malignancies, the development of novel anti-CD20 antibodies with functional activity different from that of rituximab may translate to ... |
